



MAST GROUP LTD

Mast House, Derby Road, Bootle, Merseyside L20 1EA. United Kingdom.
Tel: 0151 933 7277 Fax: 0151 944 1332
www.mastgrp.com

MAST Launch new Hain GenoType MTBDRsl

MAST are pleased to announce the launch of the new Hain Lifescience GenoType MTBDRsl kit. Based on DNA Strip technology, the assay simultaneously detects TB complex and its resistance to first and second line drugs from either culture (solid or liquid) and decontaminated smear positive pulmonary samples.

The GenoType MTBDRsl uses common mutation markers to detect resistances to ethambutol, fluoroquinolones (e.g. ofloxacin & moxifloxacin) and injectable antibiotics such as viomycin, kanamycin, amikacin and capreomycin.

When used in conjunction with the Hain Lifescience GenoType MTBDRplus the assay provides an early diagnosis of XDR-TB.

Tuberculosis is regarded as one of the major health topics globally. Currently, there are approximately 9 million cases of TB with just under 2 million deaths per year.

TB is normally a treatable disease and patients diagnosed with the disease are usually prescribed antibiotics for 6 months. The incorrect use of antibiotics in those patients with drug susceptible TB has led to the emergence of Multi Drug Resistant TB and extensively Drug Resistant TB. MDR-/XDR-TB is recognised by the WHO as one of the major threats to global health, with increased burden on duration and cost of treatment.

In 2006, 5% of all new TB cases were reported to be drug resistant and there is currently believed to be between 1-2 million people worldwide with MDR-TB and just under 500,000 with XDR-TB.

For further information on the new Hain Lifescience GenoType MTBDRsl, please contact Paul Holmes, Molecular Biology Product Manager, Mast Group Ltd on pholmes@mastgrp.com or visit the Mast website www.mastgrp.com